Literature DB >> 6928639

DNA crosslinking and cytotoxicity in normal and transformed human cells treated with antitumor nitrosoureas.

L C Erickson, M O Bradley, J M Ducore, R A Ewig, K W Kohn.   

Abstract

Normal (IMR-90) and simian virus 40-transformed (VA-13) human embryo cells were treated with antitumor nitrosoureas, and the effects on cell viability and cell DNA were compared. All six nitrosoureas tested were more toxic to VA-13 cells than to IMR-90 cells as measured by decrease in cell proliferation or in colony formation. The nitrosoureas capable of generating alkylisocyanates produced a smaller difference between the cell types than did derivatives lacking this capacity. DNA damage was measured by alkaline elution in cells treated with four chloroethylnitrosoureas. Whereas VA-13 cells exhibited dose-dependent interstrand crosslinking, little or none was detected in IMR-90 cells. The IMR-90 cells, however, exhibited at least as much DNA-protein crosslinking as did VA-13 cells. The results can be interpreted in terms of a possible difference in DNA repair between the cell lines.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6928639      PMCID: PMC348292          DOI: 10.1073/pnas.77.1.467

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Fractionation of DNA from mammalian cells by alkaline elution.

Authors:  K W Kohn; L C Erickson; R A Ewig; C A Friedman
Journal:  Biochemistry       Date:  1976-10-19       Impact factor: 3.162

2.  Effects of nitrosoureas on human DNA polymerase activities from acute and chronic granulocytic leukemia cells.

Authors:  R Y Chuang; J Laszlo; P Keller
Journal:  Biochim Biophys Acta       Date:  1976-04-02

3.  A chemical basis for the antitumor activity of chloroethylnitrosoureas.

Authors:  M Colvin; R B Brundrett; W Cowens; I Jardine; D B Ludlum
Journal:  Biochem Pharmacol       Date:  1976-03-15       Impact factor: 5.858

4.  The nitrosoureas--thoughts for the future.

Authors:  S K Carter; T H Wasserman
Journal:  Cancer Treat Rep       Date:  1976-06

5.  Inhibition of DNA repair by the 1,3-bis(2-chloroethyl)-1-nitrosourea breakdown product, 2-chloroethyl isocyanate.

Authors:  H E Kann; K W Kohn; J M Lyles
Journal:  Cancer Res       Date:  1974-02       Impact factor: 12.701

6.  Characterization of a new human diploid cell strain, IMR-90.

Authors:  W W Nichols; D G Murphy; V J Cristofalo; L H Toji; A E Greene; S A Dwight
Journal:  Science       Date:  1977-04-01       Impact factor: 47.728

7.  BCNU-modification of the in vitro radiation response in 9L brain tumor cells of rats.

Authors:  K T Wheeler; D F Deen; C B Wilson; M E Williams; S Sheppard
Journal:  Int J Radiat Oncol Biol Phys       Date:  1977 Jan-Feb       Impact factor: 7.038

8.  Chemistry and structure-activity studies of the nitrosoureas.

Authors:  J A Montgomery
Journal:  Cancer Treat Rep       Date:  1976-06

Review 9.  Nitrosoureas: a review of experimental antitumor activity.

Authors:  F M Schabel
Journal:  Cancer Treat Rep       Date:  1976-06

10.  Interstrand cross-linking of DNA by 1,3-bis(2-chloroethyl)-1-nitrosourea and other 1-(2-haloethyl)-1-nitrosoureas.

Authors:  K W Kohn
Journal:  Cancer Res       Date:  1977-05       Impact factor: 12.701

View more
  28 in total

Review 1.  Formation and repair of interstrand cross-links in DNA.

Authors:  David M Noll; Tracey McGregor Mason; Paul S Miller
Journal:  Chem Rev       Date:  2006-02       Impact factor: 60.622

2.  Repair of O6-G-alkyl-O6-G interstrand cross-links by human O6-alkylguanine-DNA alkyltransferase.

Authors:  Qingming Fang; Anne M Noronha; Sebastian P Murphy; Christopher J Wilds; Julie L Tubbs; John A Tainer; Goutam Chowdhury; F Peter Guengerich; Anthony E Pegg
Journal:  Biochemistry       Date:  2008-09-20       Impact factor: 3.162

3.  Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide.

Authors:  George C Bobustuc; Cheryl H Baker; Arati Limaye; Wayne D Jenkins; Gary Pearl; Nicholas G Avgeropoulos; Santhi D Konduri
Journal:  Neuro Oncol       Date:  2010-06-04       Impact factor: 12.300

4.  Depletion of O6-alkylguanine-DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by treatment with O6-methylguanine.

Authors:  M E Dolan; G L Larkin; H F English; A E Pegg
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Inhibition of cellular esterases by the antitumour imidazotetrazines mitozolomide and temozolomide: demonstration by flow cytometry and conventional spectrofluorimetry.

Authors:  C Dive; P Workman; J V Watson
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 6.  Drug resistance in brain tumors.

Authors:  L G Feun; N Savaraj; H J Landy
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  Clinical pharmacokinetics of oral CCNU (lomustine).

Authors:  F Y Lee; P Workman; J T Roberts; N M Bleehen
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 8.  DNA binding, nucleotide flipping, and the helix-turn-helix motif in base repair by O6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapy.

Authors:  Julie L Tubbs; Anthony E Pegg; John A Tainer
Journal:  DNA Repair (Amst)       Date:  2007-05-07

9.  Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea.

Authors:  R B Mitchell; M E Dolan
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  High-content analysis of cancer-cell-specific apoptosis and inhibition of in vivo angiogenesis by synthetic (-)-pironetin and analogs.

Authors:  Andreas Vogt; Peter A McPherson; Xiaoqiang Shen; Raghavan Balachandran; Guangyu Zhu; Brianne S Raccor; Scott G Nelson; Michael Tsang; Billy W Day
Journal:  Chem Biol Drug Des       Date:  2009-08-18       Impact factor: 2.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.